Performance in Q4 was characterized as a period of 'control' rather than acceleration, focusing on establishing a predictable and repeatable operating model. The company successfully resolved significant reimbursement uncertainty, with six of seven Medicare Administrative Contractors (MACs) now publishing payment rates for ReCell. Commercial strategy has been refined to prioritize utilization and repeat use within approximately 200 core burn and trauma centers rather than aggressive new account acquis ...

Core Insights - The company is experiencing a normalization in the utilization of its products, particularly ReCell, as reimbursement clarity improves, which is crucial for driving growth [1][2][3] - The fourth quarter of 2025 showed revenue of $17.6 million, with a full-year revenue of approximately $71.6 million, reflecting an 11% growth over 2024 [3][11] - The company expects full-year revenue for 2026 to be between $80 million and $85 million, indicating a growth of approximately 12% to 19% over 2025 [10][11] Revenue and Financial Performance - The fourth quarter revenue of $17.6 million was consistent with revised expectations, while the full-year revenue of $71.6 million marked a consecutive year of growth despite reimbursement challenges [11][12] - Gross margin for the full year was 82.1%, down from 85.8% in 2024, attributed to product mix and inventory reserves [11][12] - Operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to reduced sales and marketing expenses [13][14] Product Utilization and Strategy - The company is focusing on increasing adoption and repeated use of its products—ReCell, CoHiliX, and PermeDerm—within core burn and trauma centers, which account for roughly 90% of revenue [1][5] - ReCell remains the foundation of the business, supported by clinical evidence demonstrating faster healing and improved outcomes [6][7] - The company is transitioning from a ReCell-only strategy to a multiproduct acute wound care platform, which is expected to enhance revenue per patient opportunities [7] Reimbursement and Market Dynamics - Six of the seven Medicare Administrative Contractors (MACs) have published payment rates for ReCell procedures, alleviating previous reimbursement uncertainties [2][25] - The company is actively engaging with the remaining MAC to ensure reimbursement clarity and is optimistic about future developments [25][26] - The focus on establishing a disciplined operating model and improved visibility into cash use is expected to support execution and growth [4][14] Future Outlook - The company aims to maintain disciplined control of operating costs while supporting revenue growth with a stable cost structure [16][17] - The refinancing of debt through a new credit facility is designed to reduce operational friction and support execution [9][15] - The strategy for 2026 includes a commitment to clear reporting and execution, with a focus on delivering on established milestones [18]

Financial Data and Key Metrics Changes - Revenue for the first quarter increased by 67% compared to the same period in the prior year, reaching $18.5 million [6][25] - Gross profit margin for the first quarter was 84.7%, down from 86.4% in the same period of 2024 [26] - Net loss for the first quarter was $13.9 million, improving from a net loss of $18.7 million in the same period in 2024 [30] Business Line Data and Key Metrics Changes - The launch of ReCell Go Mini and Co Helix is expected to significantly contribute to revenue growth throughout 2025 [25][32] - The commercial lineup now includes ReCell, ReCell Go, ReCell Go Mini, Co Helix, and Permeoderm, providing a broad spectrum of products for both burn and trauma centers [14][15] Market Data and Key Metrics Changes - The US addressable market for the company has expanded from approximately $500 million to over $3.5 billion annually, marking a seven-fold increase [6][22] - The trauma market is estimated to have approximately 270,000 cases annually in the US, which ReCell Go Mini targets [10] Company Strategy and Development Direction - The company is focusing on acute wound care, stepping back from further commercial investment in the vitiligo indication due to uncertainty in reimbursement [21][56] - A significant shift in the commercial model has been implemented, transitioning from a service-oriented approach to a more focused selling-oriented approach [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for strong results driven by the expanded product portfolio and operational efficiencies [22][32] - The company expects to generate free cash flow in the second half of the year and achieve GAAP profitability in Q4 of 2025 [31][32] Other Important Information - The company has secured a waiver for its first-quarter trailing twelve-month revenue covenant with OrbiMed, which had been set at $73 million [31] - The annual meeting of stockholders is scheduled for June 4 [32] Q&A Session Summary Question: Can you share any response or performance impressions of Co Helix? - Management noted that early feedback has been positive, with a case from Ohio State demonstrating a seven-day graft readiness, which is faster than other dermal matrices [36][37] Question: How is the rollout of ReCell Go Mini going? - The response has been good, particularly from existing accounts in the trauma area, with opportunities to provide more value to trauma surgeons [41][42] Question: What are the expected revenue contributions from the new launches? - Management indicated that while they are not ready to provide specific guidance, they expect these products to be material contributors to revenue [45] Question: Is the sales force adequately staffed to meet revenue targets? - Management expressed confidence in the current staffing levels and the reconfigured sales model, which focuses on a selling-oriented approach [47][49] Question: What is the expected revenue cadence for the rest of the year? - Management anticipates steady sequential growth throughout the year, with some weighting towards the back end as new products gain traction [51][52] Question: What is the current status of the vitiligo initiative? - The company has paused spending on vitiligo due to uncertainty in reimbursement and is focusing resources on acute wound care instead [56][58]

Financial Data and Key Metrics Changes - For Q1 2025, the company's commercial revenue was $18.5 million, representing a 67% increase compared to the same period in 2024 [24] - The gross profit margin for Q1 was 84.7%, down from 86.4% in the same period of 2024, primarily due to volume discounts and product mix [25] - The net loss for Q1 was $13.9 million, improving from a net loss of $18.7 million in the same period in 2024 [28] Business Line Data and Key Metrics Changes - The launch of ReCell Go Mini and Co Helix is expected to significantly contribute to revenue growth throughout 2025 [24][30] - The company has expanded its product portfolio to include ReCell Go, ReCell Go Mini, Co Helix, and Permuderm, targeting both burn and trauma centers [13][21] Market Data and Key Metrics Changes - The US addressable market for the company has expanded from approximately $500 million to over $3.5 billion annually, marking a seven-fold increase [5] - The trauma market is estimated to have approximately 270,000 cases annually in the US, which the new ReCell Go Mini product aims to address [8] Company Strategy and Development Direction - The company is focusing on acute wound care, stepping back from further commercial investment in the vitiligo indication due to uncertainty in reimbursement [20][52] - A significant shift in the commercial model has been implemented, moving from a service-oriented approach to a more focused selling-oriented approach [15][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting to generate free cash flow in the second half of the year and achieve GAAP profitability in Q4 2025 [29][30] - The company is actively engaged in the public comment process for a proposed new technology add-on payment for ReCell, which could take effect on October 1 [20] Other Important Information - The company expects to save approximately $2.5 million per quarter in operating expenses due to recent transformations and operational efficiencies [27][29] - The annual meeting of stockholders is scheduled for June 4, encouraging participation [30] Q&A Session Summary Question: Response and performance of Co Helix during limited commercial launch - Management noted that early feedback from the limited market release of Co Helix was positive, with a notable case demonstrating faster graft readiness compared to other dermal matrices [33][34] Question: Revenue contributions from ReCell Go Mini - Management indicated that ReCell Go Mini is expected to be a material contributor to revenue, with plans to break out non-resale sales by Q3 [41][42] Question: Sales force adequacy to meet revenue targets - Management expressed confidence in the current sales force structure, which has been reconfigured to enhance selling capabilities across the product portfolio [43][46] Question: Revenue cadence expectations for the rest of the year - Management expects steady sequential growth throughout the year, with some weighting towards the back end as new product approvals are anticipated [48][49] Question: Status of the vitiligo initiative and reimbursement discussions - Management clarified that spending on the vitiligo initiative has been paused due to uncertainty in achieving reimbursement, focusing resources on acute wound care instead [52][53]